Categories AlphaGraphs, Earnings, Health Care
Everything you need to know about Biogen’s (BIIB) Q1 2023 earnings
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the first quarter of 2023.
Total revenue declined 3% year-over-year to $2.46 billion. For the full year of 2023, the company expects revenues to decline in the mid-single digit percentage and projects adjusted earnings per share in the range of $15.00 to 16.00.
Net income attributable to Biogen Inc. was $387.9 million or $2.67 per share in Q1, compared to $303.8 million or $2.06 per share last year. Adjusted earnings declined 6% to $3.40 per share.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Citigroup set to report Q4 2025 earnings. Here’s what to expect
Citigroup Inc. (NYSE: C) has undergone a sweeping transformation in recent years, emerging as a more streamlined and profitable financial institution. The bank's performance in recent quarters has underscored the
Home Depot (HD), Lowe’s (LOW): Home improvement pressures not expected to abate soon
Home improvement retailers Home Depot (NYSE: HD) and Lowe’s Companies, Inc. (NYSE: LOW) have been facing a challenging operating environment for a while now. The companies have been battling macroeconomic
Earnings Summary: AngioDynamics (ANGO) Q2 FY26 sales increase 8.8%
Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Tuesday reported an increase in net sales for the second quarter of fiscal 2026. In Q2, net sales increased 8.8% year-over-year to
